Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC
- Conditions
- Brain InjuriesConcussion, MildConcussion, BrainConcussion, IntermediateNear Point Convergence
- Interventions
- Device: BrainScope Ahead 300iP-ODiagnostic Test: SCAT5Diagnostic Test: Near Point Convergence
- Registration Number
- NCT04074486
- Lead Sponsor
- BrainScope Company, Inc.
- Brief Summary
This study is designed to collect data which will be used to associate changes in EEG, neurocognitive performance, eNPC and clinical symptoms in concussion subtypes. The study will recruit males and females, 13-50 years old, from Concussion Centers/Programs, Sports Venues and Emergency Departments (ED) across the country, over an 18-month period (Phase 2, 12 months for Algorithm Development and Norming, and Phase 3, 6 months for Validation).
- Detailed Description
Phase 1 of this project (USAMRDC W81XWH-18-C-0157) was focused on building the automated/electronic NPC capability (eNPC). This protocol is for Phase 2, in which the CI multimodal brain function biomarker will be extended (Algorithm Development) with the inclusion of an automated ocular function measurement (AOFM), to expand the capability in the characterization of concussion. The study will also expand the range of applicability of the CI to ages 13-50 years old. Phase 2 will also include norming of eNPC across the age range. Phase 3 of the project will validate the algorithms developed in Phase 2, using the same protocol.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1318
- Age ≥13 and <51 years old at time of enrollment;
- No prior history of concussion or TBI in the last 6 months.
For head injured subjects
- Having sustained a traumatic closed head injury within 120 hours (5 days from time of injury at time of BrainScope assessment);
- GCS 13-15 at time of BrainScope assessment.
For non-concussed head-injured controls
- Having sustained a traumatic closed head injury but returned to play or deemed non-concussed following sideline (on-field) evaluation within the same game and enrolled in the study within 120 hours (5 days) from said incident.
- GCS 13-15 at time of BrainScope assessment.
For matched controls and healthy volunteers
• GCS 15 at time of BrainScope assessment.
- Enrolled in any previous BrainScope clinical study;
- Current CNS active prescription medications taken daily, except for medication being taken for the treatment of Attention Deficit Disorders (ADD/ADHD); medication for smoking cessation; or medications for anxiety taken PRN (as needed);
- Forehead, scalp or skull abnormalities that prevents headset application for EEG data collection in injured/matched controls;
- History of brain tumor, brain surgery or known neurological disease including, Parkinson's, MS, Alzheimer's, dementia, epilepsy;
- History of TIA or Stroke within the last year;
- Pregnant women;
- Subjects who do not speak English (non-English speaking parents are allowed to consent so long as translation of the consent form in their native language is available);
- Acute intoxication ;
- Evidence of illicit drug abuse in the last year;
- Active fever defined as greater than 100ºF or 37.78ºC at time of BrainScope assessment;
- Subjects currently receiving dialysis or have end-stage renal disease;
- Subjects requiring advanced airway management (i.e. mechanical ventilation);
- Prisoners.
For head injured subjects
- Loss of consciousness ≥ 20 minutes related to the concussion injury;
- Evidence of abnormality visible on Computerized Tomography (CT) of the head related to the traumatic event (note: neuroimaging is not required for enrollment);
- For current injury, hospital admission (other than the Observation Unit) ranging more than 24 hours due to either head injury or collateral injuries.
For non-concussed head-injured controls
- Loss of consciousness ≥ 20 minutes related to the head impact;
- Any focal neurological signs including aphasia, apraxia, diplopia, facial droop, dysarthria/slurred speech;
- Any score >3 on a 7-point Likert scale (0=none, 6=severe) for the following symptoms at the time of BrainScope assessment (compared to how the subject normally feels): headache, dizziness, balance problems, neck pain, feeling slowed down;
For matched controls and healthy volunteers
- Any focal neurological signs including aphasia, apraxia, diplopia, facial droop, dysarthria/slurred speech;
- Hospital admission (other than the Observation Unit) ranging more than 24 hours due to either head injury or collateral injuries in the past 6 months;
- Any score >3 on a 7-point Likert scale (0=none, 6=severe) for the following symptoms at the time of BrainScope assessment (compared to how the subject normally feels): headache, dizziness, balance problems, neck pain, feeling slowed down.
For healthy volunteers
- Legally blind in one or both eyes;
- History of eye surgery in the past year;
- Any known eye disorders including age-related macular degeneration (AMD), glaucoma, lazy eye, diplopia, cataracts, etc.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Healthy Volunteer Subjects BrainScope Ahead 300iP-O Healthy Volunteer subjects are defined as those who are normal subjects i.e. not head-injured meeting specified protocol inclusion/exclusion criteria.This group of subjects are recruited only for the purpose of collecting data for norming the electronic near point convergence measurement (eNPC). These subjects will only perform a limited battery of BrainScope tests at a single visit and will include data collection regarding their demographics, concussion history, signs and symptoms, sports information, etc. These subjects will not undergo EEG or neurocognitive assessment. Non-Concussed Head Injured Subjects SCAT5 A secondary group of non-concussed head-injured controls shall be also recruited who were observed to have a head impact/injury but were not restricted from play within the same game or deemed non-concussed following on-field/sideline evaluation by the standard of care at each site. They will perform the entire BrainScope battery of tests within 5 days after the incident and defined as Day 0 and a follow-up assessment at 15 Days following Day0 Injured and Matched Control Subjects SCAT5 Head Injured subjects are defined as those who sustained a closed head injury and meet specified protocol inclusion/exclusion criteria. Matched Control subjects are enrolled based on matching criteria (for e.g. age, gender, and same population i.e. sports vs non-sports) to the head injured subjects. For all head injured and matched control group subjects, the full battery of tests will be performed. The injured pool will begin test procedures when a subject sustains a concussion injury. The matched control pool will follow the same time point/date interval as their matched injured subject. The matched control will be assigned by site to an injured subject and matched by age, gender, and sport (if applicable) or from the same population (if non-sport). Injured and Matched Control Subjects Near Point Convergence Head Injured subjects are defined as those who sustained a closed head injury and meet specified protocol inclusion/exclusion criteria. Matched Control subjects are enrolled based on matching criteria (for e.g. age, gender, and same population i.e. sports vs non-sports) to the head injured subjects. For all head injured and matched control group subjects, the full battery of tests will be performed. The injured pool will begin test procedures when a subject sustains a concussion injury. The matched control pool will follow the same time point/date interval as their matched injured subject. The matched control will be assigned by site to an injured subject and matched by age, gender, and sport (if applicable) or from the same population (if non-sport). Healthy Volunteer Subjects SCAT5 Healthy Volunteer subjects are defined as those who are normal subjects i.e. not head-injured meeting specified protocol inclusion/exclusion criteria.This group of subjects are recruited only for the purpose of collecting data for norming the electronic near point convergence measurement (eNPC). These subjects will only perform a limited battery of BrainScope tests at a single visit and will include data collection regarding their demographics, concussion history, signs and symptoms, sports information, etc. These subjects will not undergo EEG or neurocognitive assessment. Healthy Volunteer Subjects Near Point Convergence Healthy Volunteer subjects are defined as those who are normal subjects i.e. not head-injured meeting specified protocol inclusion/exclusion criteria.This group of subjects are recruited only for the purpose of collecting data for norming the electronic near point convergence measurement (eNPC). These subjects will only perform a limited battery of BrainScope tests at a single visit and will include data collection regarding their demographics, concussion history, signs and symptoms, sports information, etc. These subjects will not undergo EEG or neurocognitive assessment. Injured and Matched Control Subjects BrainScope Ahead 300iP-O Head Injured subjects are defined as those who sustained a closed head injury and meet specified protocol inclusion/exclusion criteria. Matched Control subjects are enrolled based on matching criteria (for e.g. age, gender, and same population i.e. sports vs non-sports) to the head injured subjects. For all head injured and matched control group subjects, the full battery of tests will be performed. The injured pool will begin test procedures when a subject sustains a concussion injury. The matched control pool will follow the same time point/date interval as their matched injured subject. The matched control will be assigned by site to an injured subject and matched by age, gender, and sport (if applicable) or from the same population (if non-sport). Non-Concussed Head Injured Subjects BrainScope Ahead 300iP-O A secondary group of non-concussed head-injured controls shall be also recruited who were observed to have a head impact/injury but were not restricted from play within the same game or deemed non-concussed following on-field/sideline evaluation by the standard of care at each site. They will perform the entire BrainScope battery of tests within 5 days after the incident and defined as Day 0 and a follow-up assessment at 15 Days following Day0 Non-Concussed Head Injured Subjects Near Point Convergence A secondary group of non-concussed head-injured controls shall be also recruited who were observed to have a head impact/injury but were not restricted from play within the same game or deemed non-concussed following on-field/sideline evaluation by the standard of care at each site. They will perform the entire BrainScope battery of tests within 5 days after the incident and defined as Day 0 and a follow-up assessment at 15 Days following Day0
- Primary Outcome Measures
Name Time Method Sensitivity and Specificity of the multivariate and multimodal Concussion Index 18 months for data acquisition Sensitivity and specificity of the expanded CI for assessment of the likelihood of concussion in subjects ages 13-50 who sustained a closed head injury.
- Secondary Outcome Measures
Name Time Method Efficacy of use 18 months for data acquisition The demonstration of efficacy of use of this biomarker of brain function impairment/concussion to assess readiness to return to normal activity
Identification of concussion subtypes 18 months for data acquisition Validation of subtypes (at time of injury) with different clinical characterizations and outcome (e.g., rapid versus prolonged recovery).
Trial Locations
- Locations (6)
University of Connecticut
🇺🇸Storrs, Connecticut, United States
University of Arkansas
🇺🇸Fayetteville, Arkansas, United States
Michigan State University
🇺🇸East Lansing, Michigan, United States
University of Rochester Medical Center
🇺🇸Rochester, New York, United States
University of Miami
🇺🇸Miami, Florida, United States
INOVA Health System
🇺🇸Fairfax, Virginia, United States